Alterola Biotech Stock Beta
| ABTI Stock | USD 0.01 0 25.00% |
Alterola Biotech fundamentals help investors to digest information that contributes to Alterola Biotech's financial success or failures. It also enables traders to predict the movement of Alterola Pink Sheet. The fundamental analysis module provides a way to measure Alterola Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Alterola Biotech pink sheet.
Alterola |
Alterola Biotech Company Beta Analysis
Alterola Biotech's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Alterola Biotech Beta | -6.65 |
Most of Alterola Biotech's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alterola Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Alterola Biotech has a Beta of -6.6516. This is 873.44% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The beta for all United States stocks is notably higher than that of the company.
Alterola Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alterola Biotech's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Alterola Biotech could also be used in its relative valuation, which is a method of valuing Alterola Biotech by comparing valuation metrics of similar companies.Alterola Biotech is currently under evaluation in beta category among its peers.
As returns on the market increase, returns on owning Alterola Biotech are expected to decrease by larger amounts. On the other hand, during market turmoil, Alterola Biotech is expected to outperform it.
Alterola Fundamentals
| Return On Equity | -1.27 | |||
| Return On Asset | -0.67 | |||
| Current Valuation | 68.08 M | |||
| Shares Outstanding | 807.05 M | |||
| Price To Book | 6.29 X | |||
| EBITDA | (6.47 M) | |||
| Net Income | (6.47 M) | |||
| Cash And Equivalents | 61.54 K | |||
| Total Debt | 251.18 K | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 0.10 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | 44.34 K | |||
| Earnings Per Share | (0.01) X | |||
| Beta | -6.65 | |||
| Market Capitalization | 39.55 M | |||
| Total Asset | 12.13 K | |||
| Net Asset | 12.13 K |
About Alterola Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alterola Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alterola Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alterola Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Alterola Pink Sheet
Alterola Biotech financial ratios help investors to determine whether Alterola Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Alterola with respect to the benefits of owning Alterola Biotech security.